Skip to main content
PAHC
NASDAQ Life Sciences

Phibro Animal Health Reports Strong Q3 Results, Raises Full-Year Guidance

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
8
Price
$55.08
Mkt Cap
$2.374B
52W Low
$18.89
52W High
$60.08
Market data snapshot near publication time

summarizeSummary

Phibro Animal Health reported strong Q3 results with double-digit growth in net sales, net income, and EPS, leading the company to raise its full-year fiscal 2026 financial guidance.


check_boxKey Events

  • Strong Q3 Financial Performance

    For the quarter ended March 31, 2026, net sales increased 10% to $383.5 million, net income rose 15% to $24.0 million, and diluted EPS grew 16% to $0.59. Adjusted EBITDA also increased 11% to $60.8 million.

  • Raised Fiscal Year 2026 Guidance

    The company updated its full-year fiscal 2026 guidance, increasing the lower end of several ranges. New guidance includes net sales of $1.46 billion to $1.50 billion, net income of $92 million to $100 million, and adjusted EBITDA of $247 million to $255 million.

  • Enhanced Financial Flexibility

    After quarter end, the company increased its revolving credit facility by $125 million, from $310 million to $435 million, strengthening its liquidity and operational flexibility.

  • Strategic Initiatives Launched

    Phibro announced the launch of its Sustainable Solutions Platform, including the introduction of VERRATAIN™ Verified Sustainability Solutions, indicating a focus on long-term strategic growth.


auto_awesomeAnalysis

Phibro Animal Health Corporation delivered robust third-quarter results, surpassing expectations with significant year-over-year growth across key financial metrics. The company's decision to raise its full-year fiscal 2026 guidance, increasing the lower end of several ranges, signals strong operational momentum and improved outlook. This positive financial update follows recent strategic moves, including an expanded revolving credit facility and the launch of a new Sustainable Solutions Platform, which collectively enhance the company's financial flexibility and long-term growth prospects. Investors should view this as a strong indicator of continued performance, despite a recent regulatory development in Brazil affecting certain products, which the company appears to be navigating effectively.

At the time of this filing, PAHC was trading at $55.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $18.89 to $60.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PAHC - Latest Insights

PAHC
May 22, 2026, 4:24 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
PAHC
May 06, 2026, 4:44 PM EDT
Source: Reuters
Importance Score:
8
PAHC
May 06, 2026, 4:39 PM EDT
Filing Type: 8-K
Importance Score:
8
PAHC
May 06, 2026, 4:25 PM EDT
Filing Type: 10-Q
Importance Score:
8
PAHC
Apr 30, 2026, 4:26 PM EDT
Source: Wiseek News
Importance Score:
8
PAHC
Apr 27, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
7
PAHC
Apr 23, 2026, 8:36 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
PAHC
Feb 04, 2026, 4:41 PM EST
Filing Type: 8-K
Importance Score:
8
PAHC
Feb 04, 2026, 4:16 PM EST
Filing Type: 10-Q
Importance Score:
8